← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $612B	2,350	+29	+1%	$224B
2	2 Pfizer PFE $166B	2,075	+16	+0.8%	$145B
3	3 Merck MRK $364B	1,942	+30	+2%	$130B
4	4 AbbVie ABBV $501B	1,727	+35	+2%	$71.3B
5	5 Amgen AMGN $230B	1,601	+60	+4%	$95.6B
6	6 Bristol-Myers Squibb BMY $121B	1,598	-3	-0.2%	$63.4B
7	7 Gilead Sciences GILD $190B	1,526	-48	-3%	$66.4B
8	8 Novartis NVS $279B	910	+5	+0.6%	$19.9B
9	9 GSK GSK $95.9B	787	+24	+3%	$9.34B
10	10 Regeneron Pharmaceuticals REGN $80.1B	579	+3	+0.5%	$27.9B
11	11 Incyte INCY $22.6B	509	+77	+18%	$25.5B
12	12 AstraZeneca AZN $251B	462	+12	+3%	$11.1B
13	13 Jazz Pharmaceuticals JAZZ $13.6B	306	+10	+3%	$7.59B
14	SGEN 14 DELISTED Seagen Inc. Common Stock SGEN	299	+29	+11%	$8.84B
15	15 Opko Health OPK $1.02B	245	-11	-4%	$1.05B
16	16 Myriad Genetics MYGN $397M	233	+10	+4%	$1.61B
17	CLVS 17 DELISTED Clovis Oncology, Inc. CLVS	229	+62	+37%	$2.8B
18	18 Exelixis EXEL $15.1B	229	+1	+0.4%	$5.15B
19	19 DELISTED Exact Sciences EXAS	225	+2	+0.9%	$2.41B
20	20 DELISTED Assertio ASRT	193	-11	-5%	$729M
21	21 Qiagen QGEN $9.41B	183	+165	+917%	$4.12B
22	22 Halozyme HALO $13.3B	160	-8	-5%	$1.49B
23	23 Precigen PGEN $2.64B	154	-17	-10%	$1.99B
24	24 DELISTED Radius Health, Inc. RDUS	152	-5	-3%	$1.69B
25	25 DELISTED Eagle Pharmaceuticals, Inc. EGRX	147	-2	-1%	$1.36B